Although this suggests that higher doses of ONC‐212 would be required to overcome the effects of the TME, the IC50 for ONC‐212 against healthy B‐cells (537.4 nM) was higher than against CLL cells cultured with CD40L‐fibroblasts (404 nM), suggesting a therapeutic window may be likely. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.